sarcoidosis%20-%20pulmonary
SARCOIDOSIS - PULMONARY
Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Sarcoidosis%20-%20pulmonary Diagnosis

Diagnosis

  • Diagnosis is often delayed because of the usual non-specific presentation

Diagnosis is based on the following:

  • Compatible clinical or radiologic picture or both
  • Histologic proof of non-caseating granuloma
  • Exclusion of similar diseases

Staging

Staging of Pulmonary Sarcoidosis based on Chest X-ray (CXR)

Stage 0

  • Normal CXR

Stage 1

  • Lymphadenopathy
    • Hilar & paratracheal nodes are usually involved
    • Parenchymal granulomas may be found on biopsy even in the absence of infiltrates on CXR

Stage 2

  • Lymphadenopathy w/ parenchymal infiltrates

Stage 3

  • Parenchymal infiltration w/o lymphadenopathy
  • Progressive loss of lung function may occur

Stage 4

  • Advanced fibrosis
  • Other findings include emphysema, bullae, cysts, hilar retraction & honey-combing
  • Progressive loss of lung function may occur

History

  • A thorough clinical history & physical exam should be obtained
  • Though the cause of sarcoidosis is unknown, the patient should be questioned carefully about exposure to both inorganic & organic antigens
  • Investigate possible environmental & occupational exposures that may reveal an alternative diagnosis
    • Exposure to metal dusts, fumes & organic antigens may cause granulomatous diseases that are difficult to differentiate from sarcoidosis

Extrapulmonary Disease

  • Physical exam should include a search for evidence of extrapulmonary disease
    • Evidence of multi-organ involvement is supportive of a diagnosis of sarcoidosis

Laboratory Tests

Biopsy & Histology

  • Transbronchial lung biopsy to demonstrate granulomas is recommended in most cases
    • Has a higher yield for patients w/ parenchymal lung disease seen on CXR or CT scan
  • Accessible skin lesions &/or lymph nodes may also be biopsied
  • Surgical biopsy is indicated when transbronchial or bronchial biopsies are not diagnostic & no other accessible biopsy sites are identified

Other Diagnostic Procedures/Laboratory Exams

Bronchoalveolar Lavage (BAL)

  • Increased lymphocytes are seen or an increased CD4:CD8 ratio
  • Findings are supportive, but not definitive of a diagnosis

Angiotensin Converting Enzyme (ACE) Levels

  • Elevations are not diagnostic since other diseases & granulomatous conditions may present w/ high levels of ACE
  • Additional evaluation is recommended in all patients diagnosed w/ sarcoidosis

Laboratory Exams

  • Pulmonary function tests
    • Spirometry
    • Diffusing capacity for carbon monoxide (DLco)
  • Peripheral blood counts
  • Serum chemistries
    • Blood urea nitrogen (BUN), creatinine, calcium
    • Liver enzymes: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) 
  • Urinalysis
    • Patients may present w/ hypercalciuria
  • Electrocardiogram (ECG)
    • Patients may manifest w/ cardiac arrhythmias
  • Routine ophthalmologic evaluation
    • To determine if eye involvement is present
  • Tuberculin test

Imaging

Chest X-ray (CXR)

  • Presence of bilateral hilar enlargement may speed up the diagnostic process
  • Interstitial disease alone may be seen

Computed Tomography (CT) scan

  • May be used to identify patients w/ parenchymal disease not seen on CXR
  • Demonstrates hilar & mediastinal lymphadenopathy
  • May also be done when patients present w/ atypical clinical or radiologic findings
  • Allows detection of complications of the disease (eg bronchiectasis, aspergilloma, pulmonary fibrosis)
  • Consider CT when there is clinical suspicion of the disease but the CXR is normal

Total Body Gallium Scan

  • Appearance of a Panda pattern combined w/ a Lambda pattern may support diagnosis
  • Findings are present only in a small number of patients
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Aug 2020
Adding the anti-GM-CSF* receptor-α monoclonal antibody mavrilimumab to standard care (SC) improved clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia and systemic hyperinflammation who were not under mechanical ventilation (MV), an Italian study has shown.
Pearl Toh, 08 Dec 2020
Intravenous (IV) antibiotics are no better than oral antibiotics when it comes to eradicating Pseudomonas (P.) aeruginosa in children and adults with cystic fibrosis, yet are more costly than the latter, reveals the TORPEDO-CF study.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.